AbbVie, which trades on the NYSE under the ticker ABBV, has announced encouraging top-line results from two Phase 3 trials looking at the safety and
These results are consistent with the topline results from the first parallel replicate study (Study 2) of the Phase 3 UP-AA clinical program AbbVie announced
The global neuromuscular disease therapeutics market size is estimated to grow by USD 13.73 billion from 2025-2029, according to Technavio. The market is estimated to
AbbVie announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental health impacts of a
